Editions:  Austria · Denmark · France · Germany · Italy · Norway · Spain · Sweden · Switzerland

Swiss pharma Novartis sees drop in profits

Share this article

Swiss pharma Novartis sees drop in profits
File photo: Fabrice Coffrini/AFP
11:30 CEST+02:00
Swiss drugmaker Novartis on Tuesday posted a drop in first half profits amid fierce competition for generic medicines and pricing pressures but said it was set to reach annual targets.
January-June net core income dropped five percent to $3.6 billion (3.1 billion euros), as overall first half sales dipped one percent to $23.7 billion, despite a six percent rise in volume, the group said.
   
Those volumes were buoyed by two medicines deemed to have strong potential-- heart drug Entresto and Cosentyx, a treatment for psoriasis.
   
Stiff competition for generic medicine -- not least copycat drugs for its blockbuster cancer drug Gleevec -- has eaten away some three percent of current profit margins, while price pressures have accounted for another two percent.
   
For the outlook for the year as a whole Novartis reconfirmed its objectives in saying it expected global sales this year to hit similar levels to 2016.
   
In January, the group announced total sales of $48.5 billion for 2016.
 
Get notified about breaking news on The Local

Share this article

From our sponsors

The French business school helping students craft more meaningful careers

Two MBA graduates from EMLYON Business School explain how their studies helped them to land their dream jobs working for international organisations.